{"title":"阿尔茨海默病前期主观认知能力下降的检测与干预","authors":"雅红 何","doi":"10.12677/ijpn.2022.114010","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease (Alzheimer’s disease, AD) is common in the elderly neurodegenerative diseases, and is an irreversible disease. As with other neurodegenerative diseases, AD lacks any effective treatment. Although there has been a lot of research on AD in recent years, it is a pity that so far no drug has been developed that can completely treat AD. AD is one of the most important diseases that cause death in the elderly today. Therefore, it is particularly important to diagnose and intervene in the early stage of AD, and to detect and intervene as early as possible. Subjective cognitive decline (SCD) is the first clinical manifestation in the AD continuum, and it is also the preclinical stage of AD, mainly manifested by individuals who feel a continuous decline in their cognitive function, while the cognitive evaluation shows normal. Studies have found that SCD is associated with AD biomarkers: structural and functional changes on magnetic resonance and positron emission tomography images, resulting in an increased risk of mild cognitive impairment and dementia in individuals with SCD. An association between higher education and intellectual activity levels and better cognitive performance later in life was found. Therefore, in the early stage, diagnostic identification of SCD can reduce the risk of developing AD. Using “Subjective cognitive decline” as the keyword, searching for the database, judging by the diagnostic predictors of SCD, preventing or reducing these diagnostic predictors through drug intervention and non-drug intervention of SCD can effectively reduce the occurrence of SCD to a certain extent, and then reduce the likelihood of developing AD. It is also found that there is still a controversy in both the prediction of the detection and the intervention, and more research is needed to confirm the correct statement. In conclusion, performing the detection and intervention of SCD early on has the potential to reduce the occurrence of AD.","PeriodicalId":398696,"journal":{"name":"International Journal of Psychiatry and Neurology","volume":"71 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Detection and Intervention of Subjective Cognitive Decline in Pre-Alzheimer’s Disease\",\"authors\":\"雅红 何\",\"doi\":\"10.12677/ijpn.2022.114010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alzheimer’s disease (Alzheimer’s disease, AD) is common in the elderly neurodegenerative diseases, and is an irreversible disease. As with other neurodegenerative diseases, AD lacks any effective treatment. Although there has been a lot of research on AD in recent years, it is a pity that so far no drug has been developed that can completely treat AD. AD is one of the most important diseases that cause death in the elderly today. Therefore, it is particularly important to diagnose and intervene in the early stage of AD, and to detect and intervene as early as possible. Subjective cognitive decline (SCD) is the first clinical manifestation in the AD continuum, and it is also the preclinical stage of AD, mainly manifested by individuals who feel a continuous decline in their cognitive function, while the cognitive evaluation shows normal. Studies have found that SCD is associated with AD biomarkers: structural and functional changes on magnetic resonance and positron emission tomography images, resulting in an increased risk of mild cognitive impairment and dementia in individuals with SCD. An association between higher education and intellectual activity levels and better cognitive performance later in life was found. Therefore, in the early stage, diagnostic identification of SCD can reduce the risk of developing AD. Using “Subjective cognitive decline” as the keyword, searching for the database, judging by the diagnostic predictors of SCD, preventing or reducing these diagnostic predictors through drug intervention and non-drug intervention of SCD can effectively reduce the occurrence of SCD to a certain extent, and then reduce the likelihood of developing AD. It is also found that there is still a controversy in both the prediction of the detection and the intervention, and more research is needed to confirm the correct statement. In conclusion, performing the detection and intervention of SCD early on has the potential to reduce the occurrence of AD.\",\"PeriodicalId\":398696,\"journal\":{\"name\":\"International Journal of Psychiatry and Neurology\",\"volume\":\"71 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry and Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12677/ijpn.2022.114010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry and Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12677/ijpn.2022.114010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Detection and Intervention of Subjective Cognitive Decline in Pre-Alzheimer’s Disease
Alzheimer’s disease (Alzheimer’s disease, AD) is common in the elderly neurodegenerative diseases, and is an irreversible disease. As with other neurodegenerative diseases, AD lacks any effective treatment. Although there has been a lot of research on AD in recent years, it is a pity that so far no drug has been developed that can completely treat AD. AD is one of the most important diseases that cause death in the elderly today. Therefore, it is particularly important to diagnose and intervene in the early stage of AD, and to detect and intervene as early as possible. Subjective cognitive decline (SCD) is the first clinical manifestation in the AD continuum, and it is also the preclinical stage of AD, mainly manifested by individuals who feel a continuous decline in their cognitive function, while the cognitive evaluation shows normal. Studies have found that SCD is associated with AD biomarkers: structural and functional changes on magnetic resonance and positron emission tomography images, resulting in an increased risk of mild cognitive impairment and dementia in individuals with SCD. An association between higher education and intellectual activity levels and better cognitive performance later in life was found. Therefore, in the early stage, diagnostic identification of SCD can reduce the risk of developing AD. Using “Subjective cognitive decline” as the keyword, searching for the database, judging by the diagnostic predictors of SCD, preventing or reducing these diagnostic predictors through drug intervention and non-drug intervention of SCD can effectively reduce the occurrence of SCD to a certain extent, and then reduce the likelihood of developing AD. It is also found that there is still a controversy in both the prediction of the detection and the intervention, and more research is needed to confirm the correct statement. In conclusion, performing the detection and intervention of SCD early on has the potential to reduce the occurrence of AD.